วีดีโอ

I hope everything turns out as you wish 🙏

Dear Sir, Filsuvez, also known as birch triterpenes, is a topical gel approved by the US Food and Drug Administration (FDA) for the treatment of partial thickness wounds associated with dystrophic junctional and epidermolysis bullosa (DEB; JEB) in patients 6 months and older. It was also approved by the European Commission for adults and children as young as 6 months old with wounds related to DEB and JEB 13. To obtain information about its presence in other countries, you may need to communicate with local health authorities or healthcare professionals.

shall i get in india?

There is no specific information available regarding when the generic version of Xdemvy will be released. However, pharmaceutical companies typically launch generic versions after the expiration of the patent period. This process may vary from country to country, so it may be helpful to follow local health authorities or pharmaceutical industry news. The generic version of Xdemvy, which contains the active ingredient lotilaner, may become available for patent challenges on July 24, 2027, with the potential for generic entry estimated to be around July 24, 2028. However, these dates are subject to change due to patent challenges or generic licensing. The drug is protected by six US patents and one FDA regulatory exclusivity, and it is currently available as an ophthalmic solution for the treatment of Demodex blepharitis. I hope this information is helpful. Wishing you healthy days ahead!

yes this was helpful, going thru alternative treatments currently@@Pill_Perspective

Glad it was helpful!

⭐ Thanks